CREB3L2

Across TCGA pan-cancer cohorts, CREB3L2 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated CREB3L2 data layer compared with 5 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher CREB3L2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CREB3L2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and LUAD show a favorable association.

MESO, BLCA, and KIRC are the cancer types where CREB3L2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Quartile	All	0.286	0.502	.006	66	view →
BLCA	OS	Tertile	All	0.393	0.752	<.001	62	view →
KIRC	DFS	Tertile	All	0.814	0.502	<.001	56	view →
LUSC	DFS	Quartile	II,III,IV	0.300	0.596	.003	51	view →
LGG	OS	Median	All	0.727	0.905	<.001	51	view →
STAD	DFS	Median	All	0.484	0.622	.005	37	view →
LUAD	OS	Tertile	III,IV	0.871	0.429	<.001	33	view →
UVM	DFS	Median	All	0.442	0.693	.005	22	view →
THCA	OS	Median	II,III,IV	0.929	1.000	.010	21	view →
UCS	DFS	Median	IV	0.885	0.440	.015	18	view →
ACC	DFS	Quartile	IV	0.589	0.069	.006	16	view →
CESC	DFS	Tertile	All	0.639	0.796	.009	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

CREB3L2–MESO (DFS)

Open the MESO breakdown →